Precision BioSciences (DTIL) Projected to Post Earnings on Monday

Precision BioSciences (NASDAQ:DTIL) will likely be issuing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 3, 2025 at 7:00 AM ET.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($2.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($2.04). Precision BioSciences had a negative net margin of 6,205.79% and a negative return on equity of 176.47%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $6.27 million. On average, analysts expect Precision BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Trading Down 3.0%

Shares of NASDAQ DTIL opened at $6.72 on Monday. The stock’s 50 day moving average price is $5.38 and its two-hundred day moving average price is $5.03. Precision BioSciences has a 52-week low of $3.61 and a 52-week high of $9.14. The stock has a market capitalization of $79.23 million, a P/E ratio of -0.76 and a beta of 1.72. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.66.

Hedge Funds Weigh In On Precision BioSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bridgeway Capital Management LLC bought a new position in Precision BioSciences in the 2nd quarter worth approximately $260,000. Geode Capital Management LLC grew its holdings in Precision BioSciences by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock worth $326,000 after buying an additional 4,025 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new position in Precision BioSciences in the 2nd quarter worth approximately $425,000. 37.99% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Precision BioSciences in a research report on Saturday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $47.00.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.